Tillkännagivande • Jun 01
ValiRx plc has completed a Follow-on Equity Offering in the amount of £1.005 million. ValiRx plc has completed a Follow-on Equity Offering in the amount of £1.005 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 500,000,000
Price\Range: £0.002
Security Features: Attached Warrants
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 2,500,000
Price\Range: £0.002
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing Tillkännagivande • May 21
ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.15 million. ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.15 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 75,000,000
Price\Range: £0.002 New Risk • May 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of British stocks, typically moving 9.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Revenue is less than US$1m (UK£50k revenue, or US$66k). Market cap is less than US$10m (UK£1.49m market cap, or US$1.98m). Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Share price has been volatile over the past 3 months (9.2% average weekly change). New Risk • Apr 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 3.2% per year over the past 5 years. Shareholders have been substantially diluted in the past year (98% increase in shares outstanding). Revenue is less than US$1m (UK£50k revenue, or US$67k). Market cap is less than US$10m (UK£2.30m market cap, or US$3.11m). Minor Risk Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Tillkännagivande • Nov 20
ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.74 million. ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.74 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 112,304,600
Price\Range: £0.0025
Security Features: Attached Warrants
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 183,695,400
Price\Range: £0.0025
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing Tillkännagivande • Nov 04
ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.151806 million. ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.151806 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 60,722,400
Price\Range: £0.0025
Security Features: Attached Warrants Tillkännagivande • Oct 30
ValiRx plc has filed a Follow-on Equity Offering in the amount of £0.74 million. ValiRx plc has filed a Follow-on Equity Offering in the amount of £0.74 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 112,304,600
Price\Range: £0.0025
Security Features: Attached Warrants
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 183,695,400
Price\Range: £0.0025
Security Features: Attached Warrants
Transaction Features: Subsequent Direct Listing Tillkännagivande • Jun 07
ValiRx plc, Annual General Meeting, Jun 30, 2025 ValiRx plc, Annual General Meeting, Jun 30, 2025. Location: the offices of fieldfisher llp, riverbank house, 2 swan lane, ec4r 3tt, london United Kingdom New Risk • Jun 06
New major risk - Revenue and earnings growth Earnings have declined by 1.8% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.8% per year over the past 5 years. Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Revenue is less than US$1m (UK£9.6k revenue, or US$13k). Market cap is less than US$10m (UK£1.68m market cap, or US$2.28m). Minor Risk Share price has been volatile over the past 3 months (9.1% average weekly change). New Risk • Apr 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Revenue is less than US$1m (UK£9.6k revenue, or US$13k). Market cap is less than US$10m (UK£1.87m market cap, or US$2.48m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (10% average weekly change). Tillkännagivande • Mar 27
ValiRx plc Announces Directorate Changes and Formation of New Advisory Board ValiRx Plc announced the resignation of Adrian de Courcey from its Board of Directors and that Cathy Tralau-Stewart has agreed with the Board to transition to a role as Non-Executive Director of the Company. The Company also announced the formation of its new Advisory Board which will replace its current Scientific Advisory Board. Cathy Tralau-Stewart, Chief Scientific Officer and Director of the Company, has agreed with the Board to transition to a role as Non-Executive Director of the Company with immediate effect. Cathy will be appointed as Chair of the new Advisory Board set up to deliver Scientific, Commercial and Strategic Advice to the Company. Adrian de Courcey has informed the Board that he has resigned as Non-Executive Director of the Company with immediate effect, to focus on other opportunities. During her tenure as the fractional CSO, Cathy has been instrumental in developing ValiRx's pipeline strategy, identifying, reviewing and advising on a series of Evaluation and In-licensing options. Cathy brings a wealth of experience in drug development as well as industry contacts and recognition which ValiRx wishes to retain. During Adrian's tenure as a ValiRx Non-Executive Director, he has helped the Company navigate a major strategic and organisational overhaul with the new management team to achieve significant operational efficiencies and reduce cash burn. These changes at the Board level form part of implementing a significant restructure and reduction in headcount across the Company As part of the restructure, the Company has hired a new, full time, Director of Research (non-board role), Michelle Barnard, who brings over 10 years' experience as a Senior Scientist specialising in Oncology Biology at Cancer Research Horizons and in Drug Discovery at the University of Graz prior. The Inaphaea team will also be supported by a specialist technician. These changes are expected to reduce annual costs by approximately £200,000. New Advisory Board: ValiRx has also assembled a range of experts to establish its new Advisory Board ("AB"). The initial members of the AB, in addition to Cathy Tralau-Stewart as chair, will comprise: Dr Heather Wilson Robles, a clinical oncologist and former President of the Veterinary Cancer Society, specialising in veterinary medicine is based at United Veterinary Care and Ethos Discovery based in Washington DC US. Dr Simon Wheeler, a former member of Novartis Ventures tasked with finding Veterinary medicine investments and now an Independent Animal Health and Veterinary Consultant. The AB brings a combination of scientific and commercial expertise as well as contacts within the industry. The AB also brings a balance of human and veterinary medicine expertise as the company explore opportunities to leverage the preclinical data for earlier access to the veterinary market in addition to the primary focus on the human market. New Risk • Feb 15
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 183% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (19% average weekly change). Shareholders have been substantially diluted in the past year (183% increase in shares outstanding). Revenue is less than US$1m (UK£9.6k revenue, or US$12k). Market cap is less than US$10m (UK£2.34m market cap, or US$2.94m). Board Change • Feb 05
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). CFO, Company Secretary & Executive Director James Desler is the most experienced director on the board, commencing their role in 2006. Independent Non-Executive Chairman Martin Gouldstone was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Dec 10
ValiRx plc has completed a Follow-on Equity Offering in the amount of £1.573 million. ValiRx plc has completed a Follow-on Equity Offering in the amount of £1.573 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 182,000,000
Price\Range: £0.0065
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 21,538,461
Price\Range: £0.0065
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 35,384,615
Price\Range: £0.0065
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,076,923
Price\Range: £0.0065
Transaction Features: Subsequent Direct Listing Board Change • Oct 23
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 7 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). CFO, Company Secretary & Executive Director James Desler is the most experienced director on the board, commencing their role in 2006. Independent Non-Executive Chairman Martin Gouldstone was the last independent director to join the board, commencing their role in 2024. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Tillkännagivande • Oct 18
ValiRx plc Announces Resignation of Martin Lampshire as A Non-Executive Director ValiRx plc announced the resignation of Martin Lampshire as a Non-Executive Director of the Company, effective from 18 October 2024. Martin has decided to step down from the Board of ValiRx to concentrate on his other commitments. During Martin's four year tenure as a ValiRx Non-Executive Director, he has made significant contributions to the development of the strategy and helped the Company build relationships with various City stakeholders. Tillkännagivande • Jul 25
ValiRx plc Announces Board Changes ValiRx plc announced that Martin Gouldstone, a current Independent Non-Executive Director of the Company, has been appointed Independent Non-Executive Chairman with immediate effect. In addition, the Company announces that Cathy Tralau-Stewart has been appointed to the Board as Executive Director with immediate effect and Dr. Mark Eccleston is proposed to the join the Board as Chief Executive Officer subject to standard regulatory due diligence. Dr. Mark Eccleston: Mark has worked as a scientific consultant and served on both the Commercial and Scientific Advisory Boards of ValiRx and Inaphaea gaining comprehensive knowledge of the Company's development programmes. With over 30 years' experience working in translation science in both drug and biomarker development, Mark is a former BBSRC Enterprise fellow and holds an MBA (Entrepreneurship). He is an inventor of 26 published patents ranging from peptide and CAR-T cell therapies to nucleosome enrichment as well as biodegradable chewing gum. Mark is the Managing Director of OncoLytika Ltd, a UK based technology consultancy company with a successful track record of securing grant funding (close to €3 million in Eurostar funding), strategic business development and client project management. He is also a scientific founder of several companies, including Volition, US listed biomarker company established as a spin out from ValiRx which reached a peak valuation of over $250 million. Mark currently serves as an independent scientific advisor supporting Nu.Q Discover services and sits on Volition's Scientific Advisory Board as well as being a shareholder. In addition to his commercial activities, Mark has supervised multiple industry funded PhD and Masters students at various universities, including the Open University, Greenwich University and DKFZ in Germany. He also serves as an external advisor to the Open University, contributing to modules focused on employability of biosciences graduates and employer expectations from graduates in terms of bioinformatics training. Further to the announcement on 19 March 2024, Suzanne Dilly will remain with the Company for a one-month handover period to ensure business continuity and will step down from the ValiRx Group after that period. Dr. Cathy Tralau-Stewart: Additionally, further to the announcement of 3 July 2024, the Company has appointed Dr. Cathy Tralau-Stewart as Executive Director with immediate effect. Cathy will also continue to hold the position of Chief Scientific Officer. Tillkännagivande • Jun 19
Valirx plc Announces Resignation of Kevin Cox as Chairman and Director ValiRx plc announced that Kevin Cox has resigned as Chairman and Director of the Company with immediate effect. Tillkännagivande • May 17
ValiRx plc, Annual General Meeting, Jun 20, 2024 ValiRx plc, Annual General Meeting, Jun 20, 2024. Location: the offices of dac beachcroft llp, the walbrook building, 25 walbrook, ec4n 8af, london United Kingdom Tillkännagivande • Apr 23
Valirx plc Announces Directorate Changes ValiRx plc announced that, further to the announcements of 29 February and 19 March 2024, the Company has appointed Martin Gouldstone and Adrian de Courcey as Non-executive Directors with immediate effect, following completion of standard regulatory due diligence. In addition, Ray Horn has been appointed as a Board observer. Director Appointments: Adrian de Courcey: Adrian de Courcey is a business executive with experience in both corporate and entrepreneurial environments in the UK and internationally. He began his career with KPMG and held strategy roles with Shell and Johnson & Johnson, with experience within the SME sector and built a transportation business. Adrian graduated from the University of Warwick and obtained an MBA from the University of Cambridge in 2020. Current Directorships: Inishbofin Holdings Limited, Mike De Courcey Travel Limited, Tydfil Training Consortium Limited. 1Adrian de Courcey was appointed as a director of Mike De Courcey Travel Limited on 1 July 2006. On 3 August 2021 the company was placed in a creditors voluntary liquidation. The liquidation process is ongoing, Adrian de Courcey was appointed as a director of West Midlands Transport Information Services Limited on 5 October 2011. On 21 September 2018 the company appointed a voluntary liquidator to conduct a members voluntary liquidation. The Company was dissolved 30 November 2021 with no creditor shortfall. Previous Directorships held in the past five years: Leofric Biomass Limited, West Midlands Transport Information Services Limited. Martin Gouldstone is currently CEO of Oncimmune Holdings plc and has 30 years of corporate finance and business development experience in contract research organisations, healthcare and pharmaceutical sectors. Previously, Martin was a Global Senior Vice President of Business Development at Owkin Inc., where he managed the commercial teams in the USA and Europe and led new strategic research partnerships. More recently, Martin was Chief Business Officer at Sensyne Health; Global Senior Vice President and Head of Capital Solutions for Syneos Health; Chief Business Officer at BenevolentAI. Current Directorships: hVIVO PLC (previously Open Orphan PLC), Novara Therapeutics Limited, Oncimmune Holdings PLC, Sempiternum Ltd. Previous Directorships held in the past five years: Orthopaedic Research UK. Board Change • Apr 18
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Non-Executive Chairman Kevin Cox was the last independent director to join the board, commencing their role in 2020. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. New Risk • Mar 11
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (UK£4.96m market cap, or US$6.38m). Minor Risks Latest financial reports are more than 6 months old (reported June 2023 fiscal period end). Shareholders have been diluted in the past year (47% increase in shares outstanding). Tillkännagivande • Feb 29
Valirx plc Intends to Appoint Martin Gouldstone as Non-Executive Director ValiRx Plc announced that, subject to normal regulatory due diligence, it intends to appoint Martin Gouldstone as a Non-Executive Director of the Company. Martin is currently CEO of Oncimmune Holdings plc and has 30 years of corporate finance and business development experience in contract research organisations, healthcare and pharmaceutical sectors. Previously, Martin was a Global Senior Vice President of Business Development at Owkin Inc., where he managed the commercial teams in the USA and Europe and led new strategic research partnerships. More recently, Martin was Chief Business Officer at Sensyne Health; Global Senior Vice President and Head of Capital Solutions for Syneos Health; Chief Business Officer at BenevolentAI. Martin was previously a Partner at Results Healthcare (now CG Results Healthcare), where he co-led the healthcare practice; Head of Lifesciences in the UK for BDO, M&A Lead for Europe at Quintiles (now IQVIA Inc), and held business development and licensing lead roles at Confirmant Ltd. and Sareum Holdings PLC. Martin has extensive experience buying and selling deals across Europe and the US, and in negotiating multi-year research partnerships. Currently, Martin is also a Non-Executive Director of hVIVO plc (formerly Open Orphan plc) and sits on the Board of Trustees of Orthopaedic Research UK. Martin holds a BSc in Genetics and has completed a range of postgraduate management courses. Tillkännagivande • Jan 18
ValiRx plc Announces Resignation of Stella Panu as A Non-Executive Director, Effective from 15 April 2024 ValiRx plc announced the resignation of Stella Panu as a Non-Executive Director of the Company, effective from 15 April 2024. Following the fundraise in January 2024, Stella has decided to step down from the Board to concentrate on her other commitments. Stella has agreed to a 3-month handover period to allow sufficient time for the Board to identify an appropriate replacement and ensure a smooth transition of responsibilities. During Stella's tenure as a Non-Executive Director, she has made significant contributions to the development of the strategy and the changes required to ensure the Company achieves its longer-term growth goals. Stella's expertise and guidance have been invaluable, and the Company would like to express its gratitude for her dedicated service. With Stella's support, the Company will be working diligently to identify a suitable candidate to fill the vacancy created by her departure. Tillkännagivande • Dec 21
ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.192244 million. ValiRx plc has completed a Follow-on Equity Offering in the amount of £0.192244 million.
Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 3,204,068
Price\Range: £0.06 Tillkännagivande • Dec 14
ValiRx plc, Annual General Meeting, Jan 04, 2024 ValiRx plc, Annual General Meeting, Jan 04, 2024, at 11:00 Coordinated Universal Time. Location: the offices of DAC Beachcroft LLP, 25 Walbrook London United Kingdom Agenda: To approve the issuance of the Placing Shares, the Retail Offer Shares, and the Subscription Shares. Tillkännagivande • Jun 15
ValiRx plc (AIM:VAL) acquired scientific assets of Imagen Therapeutics Limited from Imagen Therapeutics Ltd for £0.17 million. ValiRx plc (AIM:VAL) acquired scientific assets of Imagen Therapeutics Limited from Imagen Therapeutics Ltd for £0.17 million on June 14, 2023. Transaction is financed from ValiRx plc's existing resources. Liam Murray, Jo Turner and Ludovico Lazzaretti of Cairn Financial Advisers LLP acted as financial advisor to ValiRx plc in the transaction.
ValiRx plc (AIM:VAL) completed the acquisition of scientific assets of Imagen Therapeutics Limited from Imagen Therapeutics Ltd on June 14, 2023. New Risk • Jun 09
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: UK£7.89m (US$9.90m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-UK£1.7m free cash flow). Revenue is less than US$1m. Market cap is less than US$10m (UK£7.89m market cap, or US$9.90m). Minor Risk Shareholders have been diluted in the past year (39% increase in shares outstanding). Tillkännagivande • Jun 05
ValiRx plc, Annual General Meeting, Jun 28, 2023 ValiRx plc, Annual General Meeting, Jun 28, 2023, at 10:00 Coordinated Universal Time. Location: At the offices of DAC Beachcroft LLP at The Walbrook Building, 25 Walbrook, London EC4N 8AF London United Kingdom Tillkännagivande • May 26
ValiRx plc to Report Q4, 2022 Results on Jun 05, 2023 ValiRx plc announced that they will report Q4, 2022 results on Jun 05, 2023 Tillkännagivande • Jan 31
ValiRx plc Appoints Cathy Tralau-Stewart as Chief Scientific Officer ValiRx plc confirmed the permanent appointment of Dr. Cathy Tralau-Stewart as Chief Scientific Officer. Dr. Cathy Tralau-Stewart was appointed as Interim CSO for ValiRx in 2022 under a consultancy arrangement. the company now announced that Cathy has agreed to become CSO on a permanent basis, focusing on developing a risk-balanced, collaborative preclinical pipeline. She will also actively support the Company strategically through membership of the Executive team and as a Board observer. Board Change • Nov 16
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). CFO & Executive Director James Desler is the most experienced director on the board, commencing their role in 2006. Independent Non-Executive Chairman Kevin Cox was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Board Change • Sep 20
Less than half of directors are independent There are 4 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 4 new directors. 6 experienced directors. 1 highly experienced director. 2 independent directors (3 non-independent directors). CFO & Executive Director James Desler is the most experienced director on the board, commencing their role in 2006. Independent Non-Executive Chairman Kevin Cox was the last independent director to join the board, commencing their role in 2020. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of experienced directors. Recent Insider Transactions • Feb 19
Non-Executive Director recently bought UK£100k worth of stock On the 18th of February, Martin Lampshire bought around 440k shares on-market at roughly UK£0.23 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought UK£121k more in shares than they have sold in the last 12 months. Is New 90 Day High Low • Jan 13
New 90-day high: UK£0.32 The company is up 28% from its price of UK£0.25 on 14 October 2020. The British market is up 15% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. Is New 90 Day High Low • Sep 22
New 90-day high: UK£0.28 The company is up 258% from its price of UK£0.077 on 24 June 2020. The British market is down 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 9.0% over the same period. 
